Olgu Sunumu
Yıl 2021,
Cilt: 60 Özel Sayı:1 (Romatoloji), 42 - 43, 20.01.2021
Öz
Rheumatoid arthritis is the most common inflammatory disease in adults. Modifications for treatment
should be made until reaching the goals. Detailed studies should be planned for developing tailoring
therapies
Anahtar Kelimeler
Kaynakça
- Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7.
- Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15.
- Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (6): 960-77.
- Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68 (1): 1-25.
- Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 6): vi28-36.
- Acosta-Herrera M, González-Serna D, Martín J. The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis. J Clin Med 2019; 10; 8(6). pii: E826. doi: 10.3390/jcm8060826. Review
Yıl 2021,
Cilt: 60 Özel Sayı:1 (Romatoloji), 42 - 43, 20.01.2021
Öz
Romatoid artrit erişkinde en sık görülen inflamatuar artrittir. Remisyon veya düşük hastalık aktivitesi
sağlanana kadar tedavi modifikasyonları yapılmalıdır. Gelecekte yapılacak daha kapsamlı çalışmalar
ile bireyselleştirilmiş tedavilerin geliştirilmesi mümkün olabilecektir.
Anahtar Kelimeler
Kaynakça
- Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7.
- Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15.
- Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (6): 960-77.
- Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68 (1): 1-25.
- Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 6): vi28-36.
- Acosta-Herrera M, González-Serna D, Martín J. The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis. J Clin Med 2019; 10; 8(6). pii: E826. doi: 10.3390/jcm8060826. Review
Toplam 6 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Yayımlanma Tarihi | 20 Ocak 2021 |
| Gönderilme Tarihi | 6 Nisan 2020 |
| Yayımlandığı Sayı | Yıl 2021Cilt: 60 Özel Sayı:1 (Romatoloji) |
Cited By
